



# **Role of Surveillance CT in Detection of Pre-Clinical Relapse in Patients with B-Cell lymphoma: A Retrospective Study**

*Submitted for the partial fulfillment  
of the Master Degree in Radiodiagnosis*

**By:**

**Shorouq Sabry Rizq Aly**

**M.B.B.C.H.**

**Supervised By:**

**Prof. Dr. Hanan Mohammad Hanafy**

**AboZaid**

*Professor of Radiodiagnosis, Faculty of Medicine  
Ain Shams University*

# **Dr. Ahmed Hassan Soliman**

*Lecturer of Radiodiagnosis, Faculty of Medicine*

*Ain Shams University*

*Faculty of medicine*

*Ain Shams university*

*2016*

❖ **Introduction.**

❖ **Review of literature:**

*a. Classification of lymphoma.*

*b. Diagnosis and Staging.*

*c. Evaluation of treatment response.*

*d. Role of CT scan in pre-clinical relapse detection.*

❖ **Aim and objectives.**

❖ **Patients and methods.**

❖ **Results.**

❖ **Discussion.**

❖ **Conclusion.**

❖ **References.**

❖ **Arabic summary.**

# List of Figures

<b>Figure 1</b> 1832 publication on the first seven lymphoma cases (Hodgkin, 1832).....	6
<b>Figure 2</b> autopsy of Hodgkin's case number two. Abdominal lymph nodes (Stone, 2005).....	7
<b>Figure 3</b> Cover page of the 1865 paper by Sir Samuel Wilks (Bonadonna, 2000).....	8
<b>Figure 4</b> Reed-Sternberg cells as drawn by Dorothy Reed in 1902 (Lakhtakia & Burney, 2015b).....	9
<b>Figure 5</b> Karl Linnert in Keil standig infront the first version of Keil classification(Feller & Diebold, 2004).....	11
<b>Figure 6</b> histo-pathology of different subtypes of lymphoma.....	25
<b>Figure 7</b> Plain Chest X-Ray SHowing enlarged mediastinal Shadow, proved to be multiple mediastinal LNs exceeding one third of the internal transverse diameter of the thorax(Keraliya et al., 2015).....	36
<b>Figure 8</b> Pelvic CT scan of stage II follicular Lymphoma. a; pelvic mass, b; CT guided biopsy of the mass (Dupas et al., 2013).....	38
<b>Figure 9</b> MIP PET (A), transverse CT (B–D), and corresponding fused (E–G) images showed increased FDG uptake of the enlarged pulmonary (SUVmax, 5.4) and hepatic (SUVmax, 4.3) lesions, and bilateral parotid (arrows) (SUVmax, 3.6) and submaxillary (SUVmax, 4.1) glands. CT computed tomography, FDG fluorodeoxyglucose, MIP¼maximum intensity projection, PET positron emission tomography, SUVmax¼maximum standard uptake value (arrowheads)(Dong, et al., 2016).....	41
<b>Figure 10</b> Transverse CT (A–C) showed enlargement of the pulmonary lesions with air bronchogram. Transverse T1-weightedMRimage (D) showed significant enlargement of the hepatic masses with homogeneous hypointensity. These masses showed homogeneous hyperintensity on transverse (E) and coronal (F) T2-weighted MR images with confluence and minimal mass effect. The spleen became larger than before. CT computed tomography, MR magnetic resonance.....	42
<b>Figure 11</b> use of PET CT in pre-treatment staging, and in assessment of treatment response (online Library).....	48
<b>Figure 12</b> Chest CT of the same patient, image above; in an old study 6 months ago showing right middle lobe lung nodule, image below; current study showing	

complete resolution of the nodule following treatment (PACS of Radiology  
Department Ain Shams University).....51

**Figure 13** Showing patient of NHL on follow up, image above; showing newly  
developed pelvic LN in the current study compared to the same axial cuts in the  
image below: which shows no LNs in a previous study done 6 months before (PACS  
of Radiology department Ain Shams University)..... 55

## **List of Tables**

<b>Table 1</b> Rye classification system by Lukes & Butler in 1966 in which they first coined the histological appearance of HL to the prognosis of the disease(SEER training modules, 2017).....	14
<b>Table 2</b> Keil Classification of Lymphoid Neoplasms.....	15
<b>Table 3</b> Rappaport classification in 1966 that was developed before classification of Lymphoma into B and T cell subtypes (SEER training modules, 2017).....	16
<b>Table 4</b> the Non-Hodgkin's Lymphoma Pathologic Classification Project by the NCI in 1982. it represented a method of translating between the different classification systems known then. Major groups are identified by letters, A - J,grouped according to prognosis(SEER training modules, 2017).....	17
<b>Table 5</b> Updated Keil Classification(Feller & Diebold, 2004).....	18
<b>Table 6</b> Revised European-American Classification of Lymphoma(Swerdlow et al., 2016).....	19
<b>Table 7</b> 2016 Revision of WHO classification of Lymphoid.....	21
<b>Table 8</b> <i>immuno-histo-chemical and molecular characteristics of common types of lymphoma</i> (Matasar & Zelenetz, 2008).....	29
<b>Table 9</b> Ann Arbor Staging System with Cotswold Modification (Crowther & Lister, 1990).....	29
<b>Table 10</b> International Prognostic Index scoring (DuRant et al., 1993).....	33
<b>Table 11</b> Eastern Cooperative Oncology Group Performance Status (Armitage, 2005).....	34
<b>Table 12</b> F-FDG Avidity of Lymphoma According to World Health Organization Histopathologic Classificatio(Weiler-Sagie et al., 2010).....	40
<b>Table 13</b> Timing of PET scan in different types of lymphoma(Bruce D. Cheson et al., 2007).....	46
<b>Table 14</b> the 5-point scale for interpreting positive PET findings (Tilly et al., 2015).....	47
<b>Table 15</b> Revised Response Criteria BY Cheson et al., 2007.....	49
<b>Table 16</b> Guidelines for surveillance imaging by lymphoma subtype Lymphoma (Cohen & Flowers, 2014).....	62
<b>Table 17</b> Baseline patient's characteristics.....	68
<b>Table 18:</b> relapse characteristics and relapse detection method.....	70

# List of abbreviation

<b>NHL</b>	Non-Hodgkin lymphoma
<b>DLBCL</b>	Diffuse large B-Cell lymphoma
<b>HL</b>	Hodgkin lymphoma
<b>CT</b>	Computed Tomography
<b>MRI</b>	Magnetic Resonance Imaging
<b>PET</b>	Positron Emission Tomography
<b>WHO</b>	World Health Organization
<b>NHL</b>	Non-Hodgkin lymphoma
<b>FDG</b>	Fludeoxyglucose
<b>MIP</b>	Maximum Intensity Projection
<b>IWG</b>	International Working Group
<b>RECIST</b>	Response Evaluation Criteria In Solid Tumors
<b>SUV</b>	Standardized Uptake Values
<b>WB-MRI</b>	Whole-body MRI
<b>FL</b>	Follicular Lymphoma
<b>CR</b>	Complete Remission
<b>CRu</b>	Complete Resmission Unconfirmed
<b>PR</b>	Partial response
<b>SD</b>	Stationary Disease

**N**on-Hodgkin lymphoma is a fairly common tumor according to Surveillance, Epidemiology, and End Results (SEER), which states that NHL accounts for 4.3% of all new cancer cases per year in USA. Its incidence is almost doubling annually (*SEER database, 2013*). In Egypt, lymphoma is the fourth most common tumor in adults, with B-Cell lymphoma being the commonest subtype of NHL accounting for about 49% of all NHL cases presenting to NCI (*Allah HG et.al., 2014*).

With such a disease burden, and about one third relapsed NHL patients after complete remission, on-going research on new methods of detection, staging and response assessment is always making the highlights, with relapse detection being of major concern, especially with the new curative methods made available for relapsed cases. The high risk of radiation induced malignancies associated with frequent radiological follow-up scans for those long term survivors also raised the red flag for re-establishing a risk-benefit oriented follow-up plan for those patients (*Lalit et. al., 2014*).



Careful history taking, thorough physical examination and good clinical judgment are the cornerstones of an appropriate follow-up. Many recommendations have been published for formulating follow-up plans according to histology; curable versus non-curable. For curable conditions (HL, DLBCL) the likelihood of relapse decreases with time, so the frequency of follow-up decreases accordingly, and the contrary goes for non-curable conditions (mantle cell lymphoma and follicular lymphoma) (*Bruce et.al, 2014*).

Although most guidelines do not recommend whole body CT scan as part of routine follow-up for patients who went through complete remission, it is still adopted by many clinicians as part of their patients' follow-up visits. However, its value for assessment of early asymptomatic relapse is questionable, let alone its influence on the overall outcome compared to other modalities of relapse detection (*Tung-Liang Lin et. al., 2012*).

○ **Aim and objectives:**

- I. To clarify whether surveillance CT scan has a significant role in early detection of asymptomatic relapse in B-Cell lymphoma patients.
- II. To assess the contribution of image-based relapse detection to the overall survival of B-Cell lymphoma patients.


### ○ **Patients and methods:**

This is a retrospective cohort study in which 50 Patients with B-Cell lymphoma diagnosed between 2014-2016 were selected from the PACS of radiology department at Ain Shams University Hospitals. Age ranges between 20-70 year-old. All diagnoses were confirmed by histopathology studies. all patients underwent treatment and follow-up strategy as planned by their treating oncologist/hematologist, after which they entered CR or SD according to IWG Cheson criteria of treatment response.

Baseline clinical, laboratory and treatment data were abstracted from medical records. State progression was retrospectively reviewed over a period of 6 months up to 2 years. Surveillance CT scan was performed on the neck, chest abdomen and pelvis on each of the planned follow-up visits. Relapses were defined as “asymptomatic” if there were no reported symptoms and a normal examination was recorded.

### ○ **Statistical methodology:**

Overall survival (OS) after relapse was calculated from the date of relapse to the date of death for any cause or the last date of follow-up. Continuous variables were compared using *t*-test. Categorical variables were compared using Chi-Sq test. All comparisons were considered significant at *p* value < 0.05.



---

# CLASSIFICATION OF LYMPHOID NEOPLASMS

---


Chapter I



## Classification of Lymphoid neoplasms

**M**alignant transformation of lymphocytes at different stages of differentiation gives rise to lymphoid neoplasms which include lymphoma, myeloma and lymphoid leukaemia, all together compromise the sixth commonest malignancy worldwide. (Morton et al., 2007)

Having heterogeneous aetiologies, morphologies, genetic and molecular basis, lymphoma has had a very long history of classification systems since 1832 when Hodgkin reported the first description of lymphoma in his manuscript entitled “on some morbid appearances of the absorbent glands and spleen” (Hodgkin, 1832) *Figure 1*, till the most recent updated WHO classification system in 2016 (Swerdlow et



*Figure 1* 1832 publication on the first seven lymphoma cases (Hodgkin, 1832)

al., 2016)

In this early description by Thomas Hodgkin, he described autopsy findings of seven cases who had multiple lymphadenopathy *Figure 2*. He was the first to conclude that it is a disease primarily arising from lymphoid tissue and spleen. He recognized the disease grossly, and noted the orderly spread of disease through multiple lymph nodes and



*Figure 2* autopsy of Hodgkin's case number two. Abdominal lymph nodes (Stone, 2005)


the late involvement of the spleen (Stone, 2005).

When this was first published in the Medical and Chirurgical Society in London, UK, it almost passed unnoticed, until Samuel Wilks described the same disease findings on 1865 and first called it “Hodgkin’s Disease” *Figure 3*. So, it wasn’t until three decades later that Hodgkin was given the eponym for his work on describing lymphoma (Bonadonna, 2000).

Nevertheless, none of Hodgkin or Samuel had related their gross autopsy findings to histological appearance of the disease which is together with morphological appearance, immunohistochemistry as well as molecular basis now compromise indispensable parts in recognizing and diagnosing lymphoma.

Histological typing of HL using the concept of Reed-Strenberg (R-S) cell

was identified as late as 1902 by Dorothy Reed when she first depicted what she saw under microscopy, and later on was referred to as (R-S) cells *figure 4*. Since then, scientists started hunting those large cells and their variants to further classify the disease, they were described as “owel-eye”, “mirror image”, “lacunar” or “mummified” based on nuclear configuration. However, such descriptions are now liable to extinction as immuno-histo-chemical and molecular based typing is dominating over microscopic description in disease classification



*Figure 3* Cover page of the 1865 paper by Sir Samuel Wilks (Bonadonna, 2000).